TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03606044

Intervention type: DEVICE
Intervention: 3D-models
Description: The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly
Study: NCT00611533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Study: NCT04542707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue massage
Description: Graston tool
Study: NCT02484430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT05922956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial emotion recognition test
Description: Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition test
Description: Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition test
Description: Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Study: NCT01006460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea, L
Description: 3 Capsules twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis
Description: 3 capsules twice a day
Study: NCT02292199

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS Placebo
Description: TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
Study: NCT01006460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panax ginseng
Description: 3 capsules twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - dark brown sugar
Description: 3 capsules twice a day
Study: NCT01781533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: algorithm
Study: NCT02262741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab will be administered by IV infusion in combination with MEDI4736.
Study: NCT02860325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Description: Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
Study: NCT02126657

Intervention type: DRUG
Group type: OTHER
Intervention: 70% glycolic acid
Study: NCT01345734

Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
Study: NCT00006467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Study: NCT04676412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01460277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy Intervention
Description: The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Land-based exercise intervention
Description: The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
Study: NCT04676412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral capsule
Study: NCT01629563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 5 mg
Description: PGL4001 5 mg daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 10 mg
Description: PGL4001 10mg daily administration
Study: NCT03578172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotrophin
Description: experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormone replacement therapy
Description: Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
Study: NCT00530257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS-methylphenidate
Description: 18 mg to 54 mg once a day for 1 week
Study: NCT00385515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-1012 (meclocycline sulfosalicylate)
Description: tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
Study: NCT04676412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: oral capsule
Study: NCT04034082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia therapy
Description: Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
Study: NCT05379361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence Development Program
Description: It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo Training Group
Description: It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
Study: NCT03066817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]
Description: 50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propylene Glycol
Description: 50cc of propylene glycole will be given to participants as one-time dose, used as placebo
Study: NCT03517046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CartiLife
Description: Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
Study: NCT04034082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phase 2 cardiac rehabilitation programme
Description: The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
Study: NCT04034082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional phase 2 cardiac rehabilitation programme
Description: The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
Study: NCT03455582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ecological evaluation
Description: Virtual reality task and Actual reality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological evaluation
Description: Virtual reality task and Actual reality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study: NCT03416907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original consent form
Description: Participants will review the full-length, original consent form for the clinical trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortened consent form
Description: Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reordered, shortened consent form
Description: Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortened consent form with a highlights box
Description: Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive, shortened consent form
Description: Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
Study: NCT03343067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol/norethindrone acetate (E2/NETA)
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol/norethindrone acetate (E2/NETA)
Description: Capsules
Study: NCT01031602

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
Study: NCT04373174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional oximetry probe
Description: Regional oximetry probe will be placed in the frontal area of the head

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Regional oximetry probe
Description: Regional oximetry probe will be placed in the frontal area of the head

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural block
Description: Thoracic epidural block will be applied to the patients before the operation begins
Study: NCT01050543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
Study: NCT03105804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21039
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21041
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21044
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21042
Description: An electronic cigarette
Study: NCT03704987

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual-energy X-ray absorptiometry
Description: dual-energy X-ray absorptiometry

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual-energy X-ray absorptiometry
Description: dual-energy X-ray absorptiometry
Study: NCT01856907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin-Metformin
Description: Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Biguanide- insulin sensitizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Will evaluate effect of lifestyle and diet only
Study: NCT01199328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg Tablet oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg Tablet oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20 mg Tablet oral, once daily
Study: NCT03032133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional pain control
Description: Regional pain catheter
Study: NCT00385515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
Study: NCT03032133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local pain control
Description: Local intraarticular pain catheter
Study: NCT01309165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP
Description: CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Occupational Therapy
Description: Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
Study: NCT00006467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT05455164

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomalto Oligosaccharide
Description: all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
Study: NCT03096067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy slow resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate slow resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
Study: NCT02498691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Blood and saliva samples, placenta and cord blood collection
Study: NCT03948607

Intervention type: OTHER
Intervention: Electroencephalography during sustained attention task.
Description: The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3.

Intervention type: OTHER
Intervention: Electroencephalography during sustained attention task.
Description: The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3.
Study: NCT01572259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interruption of the traitment with growth hormone
Study: NCT03949842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
Description: A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
Study: NCT01295905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A contact lens
Description: Investigational silicone hydrogel, single vision soft contact lens